Loading…
MiNK Therapeutics, Inc. is projected to decline to $9.91 by 2027, a -3% move from its current price of $10.18. INKT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $9.81 | $10.18 | $10.56 | 0.00% |
| May 30 | $9.66 | $10.18 | $10.73 | 0.00% |
| May 31 | $9.55 | $10.18 | $10.86 | +0.01% |
| Jun 1 | $9.45 | $10.18 | $10.96 | +0.01% |
| Jun 2 | $9.37 | $10.18 | $11.06 | +0.01% |
| Jun 3 | $9.30 | $10.18 | $11.15 | +0.01% |
| Jun 4 | $9.23 | $10.18 | $11.23 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.23 | $10.18 | $11.23 | +0.02% |
| Week 2 | $8.87 | $10.18 | $11.70 | +0.03% |
| Week 3 | $8.59 | $10.19 | $12.07 | +0.05% |
| Week 4 | $8.37 | $10.19 | $12.39 | +0.07% |
| Week 5 | $8.18 | $10.19 | $12.69 | +0.08% |
| Week 6 | $8.02 | $10.19 | $12.96 | +0.10% |
| Week 7 | $7.86 | $10.19 | $13.21 | +0.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
The company develops agenT-797, MiNK-215, and MiNK-413 programs. agenT-797 is an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical testing in combination with botensilimab and balstilimab with ramucirumab and paclitaxel for previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trials as a monotherapy in combination with anti-PD-1 checkpoint inhibitors pembrolizumab and nivolumab for refractory solid tumor cancers; and a Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention.
The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc.
and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.
MiNK Therapeutics, Inc. trades under the symbol INKT. It currently quotes $10.87 per share, with a market capitalization of $54.15M and a rank of 4559.
The near-term price outlook around 2026 shows an average price of $10.87 with 0% ROI, essentially flat relative to today.
In 2027 the average price is projected to $10.59 with -2.6% ROI, and in 2028 the average price is $10.90 with 0.3% ROI, indicating a neutral near-term path.
From 2029 onward the forecast turns bullish, with a 2029 average of $13.75 (ROI 26.5%), a 2030 average of $15.28 (ROI 40.6%), a 2040 average of $25.41 (ROI 133.7%), and a 2050 average of $52.89 (ROI 386.5%). The max prices rise accordingly, reaching $21.06 in 2029, $24.14 in 2030, $48.44 in 2040, and $112.61 in 2050.
A major floor 28.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.4% away) — a key level to hold.
The nearest ceiling, 39.6% above — a clean break opens room to run.
A major ceiling 53.7% above — clearing it would confirm fresh momentum.
Key INKT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INKT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.63 | Sell | $10.49 | Sell |
| MA 10 | $10.58 | Sell | $10.64 | Sell |
| MA 20 | $11.02 | Sell | $10.88 | Sell |
| MA 50 | $11.01 | Sell | $11.09 | Sell |
| MA 100 | $11.24 | Sell | $11.35 | Sell |
| MA 200 | $12.40 | Sell | $11.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.81 | Neutral |
| Stoch RSI (14) | 21.70 | Neutral |
| CCI (20) | -125.13 | Sell |
| Williams %R (14) | -89.78 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -7.79 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 10.22 | Buy |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -0.81 | Sell |
| Ultimate (7,14,28) | 37.24 | Neutral |
| Momentum (10) | -1.23 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 10.62 | Sell |
| ADX (14) | 9.92 | Neutral |
| ATR (14) | 0.37 | Info |
The near-term technical picture is bearish in sentiment. The RSI14 sits at 50, while the price sits just below the 50-day moving average of $10.98, suggesting limited upside pressure in the immediate short term. The 200-day moving average sits higher at $12.42, implying continued pressure from longer-term trends.
The stock trades within a 30-day range of $8.44 to $14.00. Support is indicated at $10.04 and resistance at $14.21, which provides a defined but relatively narrow band for near-term movement. Annualized volatility is 70%, underscoring substantial price swings if volatility remains elevated.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.56 | $10.18 | $14.28 | 0% | Neutral | |
| $7.59 | $9.91 | $13.86 | -3% | Neutral | |
| $7.39 | $10.02 | $14.68 | -2% | Neutral | |
| $8.78 | $12.30 | $18.68 | +21% | Bullish | |
| $9.58 | $13.83 | $21.64 | +36% | Bullish | |
| $10.22 | $15.15 | $24.34 | +49% | Bullish | |
| $10.44 | $15.87 | $26.10 | +56% | Bullish | |
| $10.03 | $15.62 | $26.24 | +53% | Bullish | |
| $9.66 | $15.39 | $26.37 | +51% | Bullish | |
| $9.17 | $14.93 | $26.05 | +47% | Bullish | |
| $12.38 | $22.34 | $42.03 | +119% | Bullish | |
| $20.88 | $45.37 | $95.11 | +346% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $8.56 | $10.18 | $12.07 | +0.00% |
| June 2026 | $8.75 | $10.36 | $12.61 | +1.78% |
| July 2026 | $8.52 | $10.20 | $12.65 | -1.53% |
| August 2026 | $8.79 | $10.62 | $13.35 | +4.13% |
| September 2026 | $9.16 | $11.15 | $14.17 | +4.99% |
| October 2026 | $8.95 | $10.97 | $14.08 | -1.67% |
| November 2026 | $8.68 | $10.70 | $13.86 | -2.41% |
| December 2026 | $8.82 | $10.94 | $14.28 | +2.19% |
Click any year to see its month-by-month INKT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, INKT is projected to trade between $8.56 and $14.28, averaging $10.18 — a potential gain of 0% from today's $10.18. A consolidation phase looks the most probable path here.
MiNK Therapeutics, Inc.'s 2027 outlook centres on $9.91, within a $7.59 to $13.86 range. That is -3% versus the projected 2026 average. That marks a -3% change versus current levels. Price action looks broadly range-bound.
By 2028, INKT could reach as high as $14.68, with a base case around $10.02 and support toward $7.39 — roughly -2% from $10.18. A consolidation phase looks the most probable path here.
Expect INKT to range from $8.78 to $18.68 through 2029. The $12.30 average target implies a +21% move from current prices. That is up +23% on the projected 2028 average. Momentum favours further upside here.
The INKT price prediction for 2030 points to an average of $13.83 (low $9.58, high $21.64) — a potential gain of +36% on today's $10.18. Buyers look set to stay in control over this stretch.
In 2031, INKT is projected to trade between $10.22 and $24.34, averaging $15.15 — a potential gain of +49% from today's $10.18. That is up +10% on the projected 2030 average. Momentum favours further upside here.
MiNK Therapeutics, Inc.'s 2032 outlook centres on $15.87, within a $10.44 to $26.10 range. That is up +5% on the projected 2031 average. That marks a +56% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, INKT could reach as high as $26.24, with a base case around $15.62 and support toward $10.03 — roughly +53% from $10.18. Momentum favours further upside here.
Expect INKT to range from $9.66 to $26.37 through 2034. The $15.39 average target implies a +51% move from current prices. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The INKT price prediction for 2035 points to an average of $14.93 (low $9.17, high $26.05) — a potential gain of +47% on today's $10.18. Momentum favours further upside here.
In 2040, INKT is projected to trade between $12.38 and $42.03, averaging $22.34 — a potential gain of +119% from today's $10.18. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
MiNK Therapeutics, Inc.'s 2050 outlook centres on $45.37, within a $20.88 to $95.11 range. That is up +103% on the projected 2040 average. That marks a +346% change versus current levels. Momentum favours further upside here.
Investing $1,000 in INKT today (≈ 98.231827 INKT) could be worth
$4,456.51
+$3,456.51 (+346%) by 2050 · US Dollar
Based on the average projected INKT price of $45.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INKTwould be worth at today's price.
$1,000 invested in INKT on May 27, 2025 (≈ 137.174212 INKT) would be worth
$1,396.43
+$396.43 (+39.6%) today · 1.40× · US Dollar
Based on a INKT entry price of $7.29 vs. today's $10.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.72 | $949.63 | -5.0% |
| 1 month ago | $11.14 | $913.82 | -8.6% |
| 3 months ago | $11.03 | $922.94 | -7.7% |
| 6 months ago | $10.51 | $968.6 | -3.1% |
| 1 year ago | $7.29 | $1,396.43 | +39.6% |
| All time (4.6y) ago | $120 | $84.83 | -91.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INKT forecast.
Our base-case forecast reaches $20.00 around 2040.
Implied market cap at $20.00: $99.64M
The multi-year forecast points to a bullish longer-run path for MiNK Therapeutics. For 2029 the average price is $13.75 with ROI 26.5% and a bullish sentiment, rising to a 2030 average of $15.28 with ROI 40.6% and continuing upward thereafter.
From 2031 through 2035, the averages are $16.82 (ROI 54.7%), $17.81 (ROI 63.8%), $17.22 (ROI 58.4%), $17.11 (ROI 57.4%), and $16.87 (ROI 55.2%), respectively, signaling a sustained bullish trajectory with higher price levels than today.
The forecast continues to 2040 with an average of $25.41 (ROI 133.7%) and a max of $48.44, and culminates in 2050 with an average of $52.89 (ROI 386.5%) and a max of $112.61. These figures imply meaningful upside potential across the horizon, while noting that outcomes are not guaranteed and are subject to market and regulatory factors.
Tap a question to reveal the answer.
Avg $15.28, max $24.14, ROI 40.6%, sentiment BULLISH.
Forecasts show 2026 avg $10.87 (0% ROI) and 2027 avg $10.59 (-2.6% ROI), 2028 avg $10.90 (0.3% ROI). From 2029 onward, forecasts are BULLISH with rising averages and ROIs up to 386.5% by 2050.
Yes. The 2029 max is $21.06 and the 2030 max is $24.14, indicating $20 is reachable within the forecast horizon.
$8.44 to $14.00.
Current price is $10.87 and market cap is $54.15M.
MiNK Therapeutics, Inc. Community Discussion
0Share your MiNK Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.